Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A pharmaceutical combination comprising:

a) a sphingosine-1-phosphate (S1P) receptor agonist, and

b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.

Claim 2. (Original) A pharmaceutical composition for treating, alleviating or delaying progression of optic neuritis comprising an S1P receptor agonist together with one or more pharmaceutically acceptable diluents or carriers therefor.

Claim 3. (Currently amended) A combination or composition according to claim 1 ~~or claim 2~~ wherein the S1P receptor agonist is selected from the compounds of formulae I to III, IVa, IVb, and V to VII substantially as described and defined herein.

Claim 4. (Currently amended) A combination according to claim 1 ~~or claim 3~~, wherein the co-agent b) is selected from the group consisting of interferons, altered peptide ligands, immunosuppressants, adenosine deaminase inhibitors, IV immunoglobulin G, monoclonal antibodies to T-cell surface markers, TH2 promoting cytokines, compounds which inhibit expression of TH1 promoting cytokines, antispasticity agents, AMPA glutamate receptor antagonists, inhibitors of VCAM-1 expression or antagonists of its ligand, anti-macrophage migration inhibitory factor, cathepsin S inhibitors and mTOR inhibitors.

Claim 5. (Currently amended) A combination or composition according to ~~any preceding~~ claim 1, wherein the S1P receptor agonist is selected from 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol, 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol and their respective phosphate, in free form or in a pharmaceutically acceptable salt form.

Claim 6. (Original) A method for treating, alleviating or delaying progression of the symptoms of a demyelinating disease comprising co-administration of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.

Claim 7. (Original) A method for treating, alleviating or delaying progression of optic neuritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an S1P receptor agonist.

Claim 8. (Currently amended) A method according to claim 6 ~~or 7~~ wherein the S1P receptor agonist is selected from a compound of formulae I to VII substantially as described and defined herein.

Claim 9. (Currently amended) A method according to claim 6~~, 7 or 8~~ wherein the S1P receptor agonist is selected from 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol, 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol and their respective phosphate, in free form or in a pharmaceutically acceptable salt form.

Claim 10. (Original) A method according to claim 6, wherein the co-agent b) is selected from the group consisting of interferons, altered peptide ligands, immunosuppressants, adenosine deaminase inhibitors, IV immunoglobulin G, monoclonal antibodies to T-cell surface markers, TH2 promoting cytokines, compounds which inhibit expression of TH1 promoting cytokines, antispasticity agents, AMPA glutamate receptor antagonists, inhibitors of VCAM-1 expression or antagonists of its ligand, anti-macrophage migration inhibitory factor, cathepsin S inhibitors and mTOR inhibitors.

Claim 11. (Currently amended) A combination or composition according to ~~any of~~ claim~~s~~ 1 ~~to 5~~, for treating, alleviating or delaying progression of the symptoms of a demyelinating disease.

Claim 12. (Canceled)

Claim 13. (Canceled)